[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583078":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":53,"collaborators":19,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":19,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":19,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":19,"overallStatus":74,"whyStopped":19,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"T cell injection targeting CD7 chimeric antigen receptor","EXPERIMENTAL","CD7 CAR-T cell therapy Subjects meeting the inclusion\u002Fexclusion criteria will be entered into the 0.25×108, 1×108, and 2×108 CAR-T groups in sequential order, and will be administered once",[13],"Biological: T cell injection targeting CD7 chimeric antigen receptor",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Subjects who sign the informed consent form and meet the inclusion\u002Fexclusion criteria will be entered into the 0.25×108, 1×108 and 2×108 CAR-T groups, in order of priority, and will be administered 1 dose of",[9],null,[21],{"name":22,"affiliation":23,"role":24},"zhu chen, doctor","The First Hospital Affiliated to the University of Science and Technology of China","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},"CONTACT","0551-62283843","doczchen@ustc.edu.cn",{"name":31,"role":27,"phone":32,"phoneExt":19,"email":33},"qian wang, bachelor","+86 15155193878","wangqian528@mail.ustc.edu.cn",[35],{"facility":36,"status":19,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"PersonGen.Anke Cellular Therapeutice Co. Ltd","Hefei","Anhui","230088","China","CN",{"type":43,"coordinates":44},"Point",[45,46],117.28083,31.86389,{"lat":46,"lon":45},[49],{"name":50,"role":27,"phone":51,"phoneExt":19,"email":52},"Huimin Meng, doctor","+86-18015580390","huimin.meng@persongen.com",{"type":54,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100583078","clinical-study-of-cd7-car-t-cells-for-relapsedrefractory-autoimmune-diseases-100583078",false,"NCT06871644","Clinical Study of CD7 CAR-T Cells for Relapsed\u002Frefractory Autoimmune Diseases","CD7CAR-T Cell Therapy As a Single-Arm, Open-Label, Single-Center Investigator-Initiated Early-Stage Clinical Study","Inclusion Criteria:\n\n\\- Diagnosed relapsing\u002Frefractory systemic sclerosis that has failed treatment with at least two immunosuppressive and\u002For biologic agents.\n\nBone marrow and coagulation function, liver and kidney function, cardiopulmonary function are satisfied No serious mental disorders\n\nExclusion Criteria:\n\n\\- Malignancy other than AID disease within 5 years prior to screening Hepatitis B surface antigen (HBsAg) positive, AIDS, syphilis and other virus positive persons Severe heart disease","ALL","18 Years","70 Years",{"count":66,"type":67},18,"ESTIMATED","INTERVENTIONAL",[70],"NA","The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed\u002Frefractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.",[73],"Systemic Sclerosis - 2013 ACR\u002FEULAR Classification Criteria","NOT_YET_RECRUITING","2025-03-11",{"date":77,"type":78},"2025-03-12","ACTUAL",{"date":80,"type":67},"2025-03-18",{"date":82,"type":67},"2027-03-31",{"name":5,"class":6},1]